- Home
- / Gilead Sciences
Gilead Sciences
Stock Price
$75.4
2023-11-17
Market Capitalization
$94 B
2023-11-17
Revenue
$27.3 B
FY, 2022
Gilead Sciences Summary
Company Summary
- Overview
- Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes medicines. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, COVID-19, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
- Type
- Public
- Status
- Active
- Founded
- 1987
- HQ
- Foster City, CA, US | view all locations
- Website
- http://www.gilead.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Andrew Dickinson, Chief Financial Officer
Flavius Martin, Executive Vice President, Research
Jyoti Mehra, Executive Vice President, Human Resources
Operating MetricsView all
Countries
35
FY, 2021
Products
21
5.0%
FY, 2021
Phase II Trials Products (Viral Diseases)
1
66.7%
FY, 2021
LocationsView all
51 locations detected
Foster City, CA HQ
United States
333 Lakeside Dr
El Segundo, CA
United States
2355 Utah Ave
Emeryville, CA
United States
5858 Horton St #240
Miami, FL
United States
5200 Blue Lagoon Dr #450
Morris Plains, NJ
United States
300 The American Rd
Oceanside, CA
United States
4049 Avenida De La Plata
Gilead Sciences Financials
Summary Financials
- Revenue (Q3, 2023)
- $7.1B
- Gross profit (Q3, 2023)
- $5.5B
- Net income (Q3, 2023)
- $2.2B
- Cash (Q3, 2023)
- $5.7B
- EBIT (Q3, 2023)
- $2.6B
- Enterprise value
- $114.0B